If you are considering psychedelic-assisted treatment in Hungary — for yourself or for someone close to you — the honest summary for July 2026 is: one publicly funded route (esketamine, delivered through hospital psychiatry), one private route (ketamine infusion therapy in Budapest), and a research route that is currently narrow. Psilocybin and MDMA have no legal path outside trials. This guide covers who qualifies, how to start, what it costs, and where the public record simply runs out; you can begin orienting yourself with our eligibility check.
TL;DR Spravato (esketamine) is in Hungary's public drug register with 100% support on a specialist psychiatric prescription — the patient pays a 300-forint dispensing fee — but it is administered on psychiatric wards subject to prior approval, and no public list of centres exists, so everything runs through a psychiatrist. Private ketamine infusion therapy for treatment-resistant depression is available at Fájdalomklinika in Budapest, self-pay, after a psychiatric assessment. The one recruiting esketamine trial (Debrecen, Győr, Szeged) enrols adolescents with acute suicidal ideation, not adults. Psilocybin and MDMA therapy are not legally available.
At a glance
| Route | Substance | Status in Hungary | Who qualifies | Cost |
|---|---|---|---|---|
| Reimbursed esketamine | Esketamine (Spravato) | In NEAK's public drug register (PUPHA); administered on psychiatric wards with prior approval | Adults with treatment-resistant depression after at least two failed antidepressants in the current moderate-to-severe episode; also registered for psychiatric emergencies | 100% support on specialist prescription; 300 HUF dispensing fee |
| Ketamine infusion therapy | Ketamine (off-label) | Legal; offered at Fájdalomklinika in Budapest | Clinic screening; psychiatric opinion confirming treatment resistance required | Self-pay; price not published |
| Clinical trials | Esketamine | AVENUE Phase 3 recruiting in Debrecen, Győr and Szeged | Adolescents with major depression and acute suicidal ideation; study-specific criteria | Free |
| Psilocybin / MDMA therapy | Psilocybin, MDMA | Research only; no legal route | — | — |
Esketamine (Spravato): publicly supported, quietly delivered
Spravato is listed in the public drug register PUPHA maintained by Hungary's national health insurer NEAK (neak.gov.hu). On a specialist psychiatric prescription the support rate is 100%: the register shows a gross consumer price of 73,073 HUF per 28 mg device, of which insurance covers everything except a 300 HUF dispensing fee; on a normative GP prescription the support is zero, so the specialist route is the only funded one (PUPHA data via PatikaRadar).
The registered indications mirror the EU label: adults with treatment-resistant depression who have not responded to at least two different antidepressant treatments in the current moderate-to-severe episode, plus short-term use in psychiatric emergencies, always under the direct supervision of a healthcare professional (EMA EPAR). The state health portal EgészségVonal is unusually candid about how this works in practice: esketamine can currently be used only on psychiatric wards, under strict supervision and subject to prior approval, its use is characteristic of larger hospitals and clinics, and its financing is not yet comprehensive (EgészségVonal).
How to start. The route runs through a psychiatrist — your GP can refer you, or you can approach psychiatric care directly. The practical currency is a written treatment history: drugs, doses, durations, outcomes. University psychiatric departments are a reasonable place for your psychiatrist to start asking: the University of Debrecen has the country's longest track record with this class of treatment — its Kenézy Gyula university hospital gave Hungary's first documented ketamine treatment for resistant depression in 2016 (EPER/ELTE) — and its clinical centre hosts esketamine research today.
What we don't know. Neither NEAK nor the health ministry publishes a list of hospitals that administer Spravato, patient volumes, or typical waiting times, and the "prior approval" step is not documented anywhere patient-facing. The gap between supported in the register and delivered on a ward near you is real; budget time for your psychiatrist to locate an administering centre and assemble the paperwork.
Ketamine infusion therapy: the private route in Budapest
Fájdalomklinika — a Budapest pain-medicine clinic — runs a structured ketamine programme for treatment-resistant depression alongside its pain indications. Admission requires a psychiatric specialist opinion confirming treatment resistance (no lasting improvement on at least two different antidepressants), two preparatory psychological sessions precede the first dosing, and ketamine is given intravenously under medical supervision with integration support afterwards (Fájdalomklinika: ketamine therapy in depression). The clinic does not publish prices — ask for a written cost estimate covering the full course, not a single infusion, before committing. To see who is listed near you, browse providers in Hungary.
Clinical trials: active, but read the fine print
One esketamine study is recruiting in Hungary right now: AVENUE (NCT07227454), a Janssen Phase 3 trial of intranasal esketamine 84 mg added to comprehensive standard of care, started in January 2026 and is enrolling at the University of Debrecen Clinical Centre, the Petz Aladár teaching hospital in Győr, and the University of Szeged. It is not a route for adults with treatment-resistant depression: it recruits adolescents with major depressive disorder and acute suicidal ideation or behaviour. For adults, the realistic move is watching ClinicalTrials.gov and the EU CTIS registry for new Hungarian sites and browsing trial sites in Hungary; our trials guide explains how phases, placebo arms and consent work.
Psilocybin and MDMA: no route
Both remain controlled substances in Hungary with no medical-access, compassionate-use or reimbursement route, and Hungarian drug policy is among the stricter in the EU. Anyone selling psilocybin or MDMA "therapy" in Hungary today is operating illegally. If a regulated psychedelic-therapy framework matters to you, the nearest one being built is Czech medical psilocybin — see our Czechia guide — and trials elsewhere in Europe remain the legal research route.
What to expect in treatment
Whichever route you take, the shape of care is similar and worth picturing in advance. Treatment begins with a screening appointment: the clinician reviews your psychiatric and medication history, checks your cardiovascular health and current medicines, and confirms the diagnosis before anything is scheduled. This is also where contraindications are caught.
On a Spravato day you self-administer the nasal spray in the practice or clinic under supervision, then stay for an observation period of roughly two hours while staff monitor blood pressure, heart rate and how you feel; dissociation and a temporary rise in blood pressure are expected and settle as the drug clears. You must not drive for the rest of the day, so arrange a ride home. Induction is typically more frequent at first and then tapers based on measured response, always combined with a continuing oral antidepressant.
A ketamine infusion is usually given intravenously over about 40–60 minutes with the same vital-sign monitoring and a recovery period afterwards; KAP programs wrap the dosing in preparation and integration sessions with a therapist. Where a legal psychedelic-therapy route exists (a compassionate-use programme, a regulated PAT programme or a clinical trial — availability differs by country), dosing days are long and closely supervised — two trained professionals including a physician stay with you — and sit inside a broader plan of preparation, general psychiatric care and integration. In every setting the medicine is one part of the plan: screening, monitoring and follow-up are what make it safe, and psychotherapy or integration is what helps the effect last.
Risks and who should not start
These treatments are generally well tolerated under supervision, but they are not for everyone, which is exactly what screening is for. Common, transient effects during or shortly after a session include dissociation (a detached, dreamlike feeling), nausea, mild perceptual changes, and a short-lived rise in blood pressure and heart rate; these resolve as the drug is metabolised. Treatment may be inappropriate, or require particular caution and specialist evaluation, when any of the following apply:
- Uncontrolled hypertension or significant cardiovascular instability, including a history of aneurysmal vascular disease, because of the temporary rise in blood pressure.
- A personal or family history of psychosis or bipolar disorder — a particular caution for classic psychedelics such as psilocybin, which legal programmes screen for carefully.
- Pregnancy or breastfeeding.
- Substance-use concerns, particularly patterns of compulsive use.
A responsible provider screens for all of these before the first dose. If a clinic is willing to treat you without that assessment, treat it as a warning sign — see our clinic-choice guide. To see who is listed near you, browse providers in Germany.
Frequently asked questions
Is Spravato reimbursed in Hungary?
Yes, with a practical catch. The drug carries 100% support on a specialist prescription — a 300-forint dispensing fee against a 73,073-forint gross price — but administration happens on psychiatric wards subject to prior approval, so coverage on paper only becomes treatment once a psychiatrist at an equipped hospital takes your case.
How do I find a hospital that administers it?
There is no public list. Ask your psychiatrist to enquire with university psychiatric departments and large hospital psychiatry units; bring a complete written treatment history, because documented failure of two adequate antidepressant trials is what moves the file.
What does private ketamine therapy in Budapest require?
A psychiatric specialist opinion confirming treatment-resistant depression, then the clinic's own assessment: two preparatory psychological sessions before the first supervised infusion. Prices are not published, so request a written quote for the whole course.
Can adults join the esketamine trial in Debrecen, Győr or Szeged?
No. AVENUE enrols adolescents with major depression and acute suicidal ideation or behaviour. Adults should watch the registries for new Hungarian studies instead.
Sources
- NEAK: Publikus Gyógyszertörzs (PUPHA) — public drug register
- PatikaRadar: Spravato 28 mg — NEAK/PUPHA support and co-payment data
- EgészségVonal (state health portal): Newer therapies for mental disorders — esketamine availability in Hungary
- Fájdalomklinika: Ketamine therapy in depression — admission criteria and process
- Fájdalomklinika — pain and ketamine clinic, Budapest
- ClinicalTrials.gov: NCT07227454 — AVENUE, intranasal esketamine in adolescents (recruiting; Debrecen, Győr, Szeged)
- EPER/ELTE: The role of ketamine in treating depression — first Hungarian ketamine treatment in Debrecen, 2016
- EMA: Spravato (esketamine) EPAR
- PHARMINDEX: Spravato 28 mg — Hungarian product information
This guide is for general information only and is not medical advice, a diagnosis, or a recommendation of any treatment. Support rules and hospital practice can change; always verify current requirements with NEAK, the prescribing psychiatrist, or a licensed clinician who knows your history. If you are in crisis, contact your local emergency number or a crisis line immediately.
This guide awaits review by a licensed medical professional.